Linfield University

DigitalCommons@Linfield
Senior Theses

Student Scholarship & Creative Works

5-1-2012

Effects of Maternal Low Protein Diet on Expression of Drug
Transporters in the Blood-Brain Barrier of Adult Offspring
Bonnie L. Hastings
Linfield College

Follow this and additional works at: https://digitalcommons.linfield.edu/biolstud_theses
Part of the Medicinal Chemistry and Pharmaceutics Commons, and the Molecular and Cellular
Neuroscience Commons

Recommended Citation
Hastings, Bonnie L., "Effects of Maternal Low Protein Diet on Expression of Drug Transporters in the
Blood-Brain Barrier of Adult Offspring" (2012). Senior Theses. 1.
https://digitalcommons.linfield.edu/biolstud_theses/1

This Thesis (Open Access) is protected by copyright and/or related rights. It is brought to you for free via open
access, courtesy of DigitalCommons@Linfield, with permission from the rights-holder(s). Your use of this Thesis
(Open Access) must comply with the Terms of Use for material posted in DigitalCommons@Linfield, or with other
stated terms (such as a Creative Commons license) indicated in the record and/or on the work itself. For more
information, or if you have questions about permitted uses, please contact digitalcommons@linfield.edu.

Signature redacted
Signature redacted
Signature redacted

Signature redacted

Signature redacted

Maternal LPD and drug transporters of BBB 2
Abstract
Adverse uterine environment, manifested as low birth weight (LBW), has been shown to
predispose individuals to hypertension, diabetes, and obesity by mechanisms that are just
beginning to be understood. One of the mechanisms is the dysregulation of the
expression or function of drug transport proteins, such as the organic anion transporter
(OAT) family, which are crucial for the transport of various endogenous and exogenous
compounds into and out of all organs, especially the brain. Hence, we examined the
status of select drug transporters in the blood-brain barrier (BBB), using a LBW rat
model. Maternal low protein diet (LPD) during gestation and lactation is a widely used
animal model to induce LBW. Indoxyl sulfate, a substrate for Oat3, is found in lower
concentrations in the brain tissue of LBW rats and higher concentrations in the serum, as
analyzed by HPLC. In support of these data, an increase in the protein expression of
Oat3, an efflux transporter, was observed in the LBW group. On the contrary, the BBB
mRNA expression of Oat3, and other drug transporters Oatp1c1, Oatp1a4, and P-gp in
LBW rats was found to be decreased compared to normal birth weight rats. Most
notably, we found an almost 100-fold decrease in the expression of Oat3 in low birth
weight male rats. In summary, large scale differences in the expression and function of
drug transporters in the brains of LBW individuals could not only affect the action of
exogenous pharmaceutical agents, but also the ability of the brain to maintain
homeostasis by balancing the concentrations of endogenous compounds.
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Introduction
Individuals with low birth weight (LBW) have been shown to have increased risk
of developing several chronic diseases. A forerunner in the research of the LBW
condition, Dr. David Barker, has established a correlation between LBW and the adult
onset of heart disease, hypertension, and metabolic syndrome1,2,3. Others have also
observed the deleterious effects of LBW such as a study of monozygotic twin pairs in
Denmark, which revealed a greater risk of developing diabetes in the twin with lower
birth weight4.
LBW is defined as weighing less than 2,500 grams or 5.5 pounds at birth5. There
are several reasons why an infant might weigh less than this standard. Premature birth
obviously contributes to the number of infants born with this characteristic, but insults to
fetal development leading to growth restriction during pregnancy can also cause this
effect. The World Health Organization in its 2004 report on LBW cited that infants are
more likely to be born to women living in deprived socioeconomic conditions, women
whom are undernourished and in poor health themselves, and women who do physically
demanding labor. In short, the maternal characteristics associated with LBW are mostly
attributable to conditions of poverty.
LBW is a condition which is typically more prevalent in developing rather than
developed countries. The proportion of infants born with LBW in developed countries is
7% compared to developing countries where the rate is 16.5%, more than two times
higher5. Interestingly, LBW is more common in the United States than in other developed
countries6, with 8% of infants born LBW in 20025 which is slightly higher than the
average for developed countries.
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Several animal models have been developed to study LBW. Because LBW is so
closely linked to maternal nutrition, several of the models restrict a key nutrient in the
maternal diet. Studies have demonstrated that LBW can be induced by intrauterine
glucocorticoid exposure, ligation of the uterine artery, or by maternal diets that are
restricted in protein, iron, or total calorie intake7. The protein restriction model has been
verified by our lab to decrease birth weight in rats, making the maternal low protein diet
(LPD) a good model to study the LBW condition8.
Programming is the term used to describe “…the process whereby a stimulus or insult at
a critical period of development has lasting or lifelong effects.” 9 This “programming effect” has
been witnessed in the morphological and functional differences in the organs of LBW animals.
Burns, et. al. found that maternal protein restriction in rats resulted in offspring with impaired
glucose tolerance and livers which contained half the number of lobules10. Additionally,
Zimanyi, et. al. observed that maternal protein restriction produced LBW in offspring, decreased
offspring kidney size, and reduced the number of nephrons by 30%11.
Although many organs are modified by fetal programming, there is evidence that
indicates that the brain is protected from insult in utero. This “brain protective effect” might be
mediated by redistribution of blood flow. Campbell, et. al. observed increased carotid and
cerebral blood flow and vasodilatation in mature fetal sheep in response to asphyxia that was
produced by occlusion of the umbilical cord or by impeding ventilation by stopping the
respiratory pump12. This was corroborated by work by Rudolph, et. al. which showed that under
conditions of hypoxic stress, circulation in fetal sheep is redirected to provide well-oxygenated
blood to the brain and heart 13.
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There is also evidence, however, that the brain might not be as impermeable to in utero
insult as previously thought. Maternal LPD resulted in decreased blood vessel density in the
cerebral cortex (measured both as vessel length and vessel perimeter), and this effect was not
recoverable with a normal diet 14. In addition, Plagemann, et. al. observed aberrations in neuron
number as well as changes in the expression of neuropeptide Y in the hypothalamic nuclei of the
offspring of maternal LPD rats15. Finally, Cherala, et. al. observed that when dosed with the
sleep-inducing barbiturate, hexobarbital, LBW female rats exhibit a significantly shorter sleep
time16. Taken together, these studies indicate that fetal programming results in morphological
and physiological changes in the brain.
One explanation for the decreased hexobarbital sleep time in LBW female rats, as
observed by Cherala et. al., might be that hexobarbital is metabolized more quickly in LBW rats.
The hexobarbital sleep time test is a measure of the function of the P450 enzyme superfamily.
Cherala et. al., found that there were no differences in the activity of hexobarbital hydroxylase
and no differences in the amount of CYP2C12 protein in the liver, which is one of the principal
P450 enzymes for hexobarbital metabolism16. In light of this discovery, it is possible that
hexobarbital is not metabolized more quickly and thus less is made available to induce sleep in
LBW female rats, but perhaps less hexobarbital is reaching their brains, or alternatively, more
hexobarbital is effluxed out of the brain, although an equivalent amount of the compound is in
the circulation.
Pharmacokinetics concerns itself with the movement of substances into, around, and out
of the body and is studied by observing drug absorption, distribution, elimination, metabolism,
and excretion17. Endogenous and exogenous compounds enter and exit various compartments of
the body by a variety of mechanisms including diffusion (both active and passive), and
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facilitated transport into different cell types by membrane-bound transport proteins, often
referred to as drug transporters. Additionally, a very diverse complement of enzymes
metabolizes compounds into different forms which help these substances to either be utilized or
removed from the body. LBW has been associated with changes in the morphology and
physiology of the liver and kidneys; key organs in pharmacokinetic study, which play important
roles in how pharmacologically active compounds enter the body, are introduced to the
circulation, and are a excreted10,11,18.
So how might LBW affect pharmacokinetics in the brain? One mechanism is by
modifying the expression or function of transporters at the blood-brain barrier (BBB). The BBB
is critical for maintaining the correct ion concentrations in the interstitial space, supplying
essential nutrients to the brain, and flushing out waste products into the circulation19. The BBB is
comprised of the brain microvascular endothelium, forming an interface between the systemic
circulation and the interstitial space of the brain which contains more than 100 billion
capillaries20. The endothelial cells of the BBB form tight junctions with one another, permitting
the diffusion of only small molecules with high lipid solubility and low molecular mass 21.
Transport proteins expressed on both the abluminal and luminal membranes of BBB endothelial
cells selectively bind substrates for either influx into the interstitial space of the brain or efflux
into the systemic circulation.
Drug transporters are critical to the role of the BBB in maintaining homeostasis and
protecting the brain from toxic accumulation of xenobiotics22. One of the families of transport
proteins that are expressed in the BBB is the organic anion transporter (OAT) family. The
proteins Oat3, Oatp1c1, Oatp1a4, and P-glycoprotein (P-gp) were chosen as representative
organic-anion transporters which vary in their localized expression (abluminal or luminal
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membrane of BBB endothelial cells) and in their directional transport (influx or efflux). Figure 1
shows a schematic which represents the localized expression and directional transport of each
protein.
Figure 1: Diagram of representative organic-anion transporters and their expression loci
in BBB endothelial cells.

Sources: Roberts (2008), Urquhart (2009), Bauer (2008).
These transporters are responsible for the flux of a variety of different substrates
into ant out of the brain interstitial space. Table 1 shows several examples of substrates of
each transporter.
Table 1: Examples of substrates for each transporter
Transporter
Substrates
OAT3
Indoxyl sulfate26, para-aminohippurate24
P-gp
Some chemotherapy drugs24, cyclosporin A24
OATP1C1
Thyroxine27
OATP1A4
Digoxin27
The present study was undertaken to determine whether the LBW condition
affects the expression and, or function of transporters in the brain tissue. Indoxyl sulfate,
a uremic toxin, was measured in cerebral cortex and in serum to assess the function of
OATs in the BBB, namely Oat3. Protein and mRNA expression experiments were
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conducted to assess whether altered transport of solutes is due to altered function or
aberrant expression.
Methods
Diets
Modified isocaloric versions of the AIN76A purified diet were purchased in pellet form from
Purina Test Diets (Richmond, IN). The control and low protein diets contained 19% and 8%
casein, respectively. Detailed compositions of both diets are available in the literature8.
Experiments with dams
This study was approved by the Institutional Animal Care and Use Committee of the Oregon
Health & Science University, Portland, OR. Virgin female Sprague-Dawley rats (Charles River
Laboratories, Inc., Wilmington, MA) were mated by housing one male rat with two female rats.
Day 1 of pregnancy was assigned upon observation of sperm in the daily morning vaginal
smears, at which time rats were randomly assigned to the two diet groups; control or low protein.
Each treatment group consisted of 5-7 pregnant rats, and these rats received their assigned diet
throughout pregnancy and lactation.
Experiments with offspring
Upon birth, litter size and sex of pups was noted. All litters were randomly culled to 12 pups (6
male and 6 female) on the day of birth and further randomly culled to 8 pups (4 males and 4
females) on day 4 after birth. Offspring from both groups were weaned on day 28 after birth and
were housed in iso-sexual groups according to perinatal diet treatment. Different dietary
treatments were administered only during gestation and lactation, and all pups were weaned onto
a non-purified diet. On day 120 after birth, a single blood draw from the medial saphenous vein
was performed on two male and two female offspring from each litter, serum was isolated within
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30 minutes of blood collection, and stored at -80°C.Two male and two female offspring from
each litter in both groups were randomly chosen and sacrificed on days 90 and 150 after birth.
Brain was collected from all sacrificed animals, weighed, snap-frozen in liquid nitrogen and
stored at -80°C.
RNA isolation
Cortex tissue (100-200mg) was homogenized with mortar and pestle over liquid nitrogen, and
total RNA was extracted from sample using the TRIZOL method according to the
manufacturer’s protocol and stored at -80°C. Purity and concentration of the RNA product was
assessed by measuring A260/230 and A260/280 values, respectively (Nanodrop 1000, ThermoScientific, Wilmington, DE).
cDNA synthesis
cDNA was generated using iScript cDNA synthesis kit (BioRad, Hercules, CA). Briefly,
approximately 1µg of RNA was added to reaction mixture containing iScript reaction mix,
iScript reverse transcriptase, and nuclease-free water to a final reaction volume of 20µl. cDNA
synthesis was conducted using the BioRad MyiQ thermocycler. Concentration of cDNA was
assessed by measuring A260/280 value (Nanodrop 1000), and samples were stored at -20°C.
Real-time polymerase chain reaction (RT-PCR)
cDNA (10-20 ng) was added to a reaction mixture containing iQ SYBR Green supermix
(BioRad, Hercules, CA) and forward and reverse primers; (250nM concentration, see table 2) to
a final reaction volume of 20 µL. PCR amplification was performed in the BioRad MyiQ
Thermocycler as follows: 2 minutes at 95˚C, followed by 40 cycles of 95˚C for 20 seconds and
50˚C for 30 seconds. RT-PCR was conducted in triplicate for each sample. Each RT-PCR plate
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was run with a negative control (water), and a positive control (a randomly selected control
sample, which was the same for every plate).
Table 2: Primer sequences for PCR study.
Gene
Accession #
GAPDH
NM_017008
Forward
Reverse
HPRT1
XM_217584
Forward
Reverse
GUSB
NM_017015
Forward
Reverse
TBP
NM_001004198 Forward
Reverse
β-Actin
NM_031144
Forward
Oat3
P-gp
Oat p1a4
Oatp1c1

NM_031332.1
NM_012623.2
NM_131906.1
NM_053441.1

Sequence
GTGGTGCCAAAAGGGTCAT
ATTTCTCGTGGTTCACACCCA
GCCCCAAAATGGTTAAGGTTG
TCCACTTTCGCTGATGACACA
TCACTCGACAGAGAAACCCCA
CTCTGGTTTCGTTGGCAATCC
CGGTTTGCTGCAGTCATCAT
GTGCACACCATTTTCCCAGA
GCCAACACAGTGCTGTCTG

Reverse

CACATCTGCTGGAAGGTGG

Forward

AGCCGTGCTTGGATGGCTGGAT

Reverse

GCTGCACACCAAGTCCCACTCT

Forward

CCGCATTCTGCCGAGCGTTACT

Reverse

AGACGTCATCTGTGAGCCGGGT

Forward

AGTCTCAGCATGGAGAGGACCGT

Reverse

ACACACTCTGAGGGGTCTTGTGT

Forward

TGACTTCTACCTCCAGGCCGGGAT

Reverse

CCGGCAGGTTGCGCTGAATT

PCR data analysis
The efficiency (E) of primer pairs was determined using a 10x serial dilution of a control cDNA
sample28. The slope of the relationship between Log transformation of dilution factor and cycle
threshold (Ct) values at each dilution factor was calculated. The ‘E’ of each primer pair was then
calculated as 10^(-1/slope). Reference gene was chosen by determining housekeeping gene
which changed least in expression between diet, age, and sex. In brain, GAPDH varied least
across treatment groups and was used as the reference gene. Fold differences in the expression of
a reference gene between groups were calculated as E^(∆Ct (control-LPD)). Theoretical effects on
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target gene expression were calculated by the method adapted from Pfaffl method 29. A
substantial change in gene expression is considered to be a fold difference of more than two.
Plasma membrane isolation
Cerebral cortex was homogenized according to Naud, with some modifications30. Briefly,
approximately 500mg cerebral cortex was homogenized with a dounce homogenizer in 8mL
buffer containing 250mM sucrose, 5mM Tris/HEPES, and 0.1mM PMSF. An aliquot of total
homogenate was taken at this point and stored at -80°C for later HPLC analysis. To isolate
plasma membrane fraction, the remaining homogenate was centrifuged at 9000xg for ten minutes
at 4°C. The supernatant removed and then centrifuged at 33,000xg for 60 minutes at 4°C. The
supernatant was aspirated and the pellet, containing plasma membranes, was resuspended in
saline buffer (1x PBS, 0.1mM PMSF) and stored at -80°C.
Polyacrylimide gel electrophoresis
Crude plasma membrane samples were assayed for protein concentration using the Bradford
method and equal concentrations of protein were subjected to western blotting. Briefly, samples
were reduced with laemmli sample buffer (Bio-Rad, Hercules, CA) and denatured in a 100°C
water bath for 3 min. For brain plasma membranes, 20µL of each sample was loaded onto a
10% polyacrylimide gel and subjected to electrophoresis at 150mV for 60 minutes.
Western blotting
Samples were then transferred onto a nitrocellulose membrane, blocked with blocking buffer
(LiCor Biosciences, Lincoln, NE), and incubated with a 1:1000 concentration of primary rabbit
anti-rat OAT-3 antibody (Alpha-Diagnostic, San-Antonio, TX). The membrane was then
incubated with 1:15000 concentration IRDye 680RD secondary goat anti-rabbit antibody (LiCor
Biosciences, Lincoln, NE) before being imaged on Odyssey Imaging System (Licor Biosciences,
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Lincoln, NE). For quantification, band intensity was quantified using NIH ImageJ software, and
normalized to a control sample run on every gel.
Quantitation of indoxyl sulfate
A modified high-performance liquid chromatography (HPLC) was used to quantify indoxyl
sulfate in brain tissue and serum, as described by Tsutsumi et.al31. Briefly, 10 μL of total brain
homogenate was treated with acetonitrile, vortexed, and centrifuged at 8,000xg for 10min. Two
μL of the supernatant was injected onto a 4.6mmX100mm, 2.6m Kinetex C18 analytical column
(Phenomenex, Torrance, CA) maintained at 34oC and fitted with Waters Symmetry C18 guard
column (3.9mm X 20mm; 5m particles). The mobile phase consisted of 84/16 v/v of acetate
buffer (0.2M, pH 4.5)/acetonitrile at a flow rate of 1.0 mL/min. Indoxyl sulfate was monitored
using fluorescence detector at 280 nm (excitation) and 375 nm (emission). The fluorescence
reading was converted into indoxyl sulfate concentrations using a standard curve (0-200 ng/mL).
The intra- and inter-day coefficients of variation were <5%.
Data analysis
Differences in brain and serum indoxyl sulfate and brain Oat3 expression were calculated using
t-test for treatment group comparisons. Statistical analysis conducted at α=0.05 (SigmaPlot
v11.0, San Jose, CA). To assess differences in reference gene expression, two-way ANOVA was
conducted with Student-Newman-Keuls post-hoc analysis on the cycle threshold (Ct) values
(SigmaPlot v11.0, San Jose, CA). Transporter Ct values were normalized to GAPDH, and fold
differences greater than two are accepted as significant.
Results
There was significantly more indoxyl sulfate in the serum of female LPD rats than in the
serum of female control rats at day 150 (see figure 2). Males followed a similar trend, but the
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difference was not significant. Additionally, there was a significantly decreased concentration of
indoxyl sulfate in the brain tissue of LPD rats of both sexes compared to control rats at day 150
(see figure 3).
Figure 2: Indoxyl sulfate in serum.
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Significant difference observed in females (0.006), but not in males
(p=0.238).

Figure 3: Indoxyl sulfate in brain tissue.
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Western blot analysis of protein expression showed that female LPD rats expressed
significantly more Oat3 protein in the cortex plasma membrane fractions than their control diet
counterparts. Males, however, expressed slightly less (see figure 4).
Figure 4: Expression of Oat3 protein in cortex plasma membrane.
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Significant difference observed in females (p<0.001), but not in males,
(p=0.75).

The expression in the brain of several commonly used reference genes was compared so
as to select a reference gene whose expression is unchanged by the low-protein diet model. The
expression of HPRT1 was decreased in LPD individuals of both sexes at day 150. LPD females
at day 90 also express less HPRT1. However, males at day 90 exhibit the opposite pattern, and
the LPD group expresses more HPRT1 than the control group. Significant differences were also
found in the expression of BA. At day 90, both male and female LPD express more BA than their
control counterparts, but this effect did not occur in females at day 150, and male LPD at day
150 still actually express significantly less BA than controls. See table 3.
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Table 3: Effect of maternal LPD on brain mRNA expression of select reference genes in day
150, and 90 old male and female offspring.
Age Gene
Females
Males
Control
GAPDH

Day 150

HPRT1

GUSB

BA

GAPDH

Day 90

TBP

HPRT1

GUSB

BA

LPD

22.60±

23.96±

0.67

0.27

(2.95)2

(1.10)

22.10±

31.77±

0.32

7.10

(1.47)

(22.33)

26.47±

27.21±

0.24

0.93

(0.89)

(3.41)

18.03±

22.32±

0.25

2.69

(1.37)

(12.06)

23.08±

25.12±

1.02

0.48

(4.41)

(1.91)

25.63±

27.18±

0.24

0.38

(0.94)

(1.41)

22.60±

35.90±

0.42

7.10

(1.84)

(19.78)

26.80±

27.74±

0.46

0.33

(1.70)

(1.18)

19.12±

24.92±

0.85

0.37

Fold

Control

Diff.1
-2.19

303.54
**
-1.60

13.26

-3.25

22.59±

24.26±

0.67

0.18

(2.98)

(0.73)

23.06±

35.99±

0.37

6.94

(1.58)

(19.27)

26.70±

26.97±

1.16

0.38

(4.36)

(1.41)

18.76±

24.16±

0.58

0.58

(3.11)

(2.42)

24.91±

22.45±

0.47

0.19

(1.90)
-2.24

LPD

26.78±

Fold Diff.
-2.62

2086.50
**
-1.19

-25.88
*
4.14

(0.83)
25.40

2.22

34.88±

22.27±

1724.1

8.00

0.23

0.54
(2.03)

2598.11
**
-1.80

32.73

(22.94)

(1.03)

27.85±

26.43±

0.35

0.47

(1.25)

(1.79)

23.72±

17.91±

1.68

0.42

8
**
2.43

33.07
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(4.47)

(1.49)

*

(7.08)

(2.37)

1

Fold differences in the expression of gene in LPD group offspring, compared to the control
group offspring; 2 The Ct values are expressed as mean±S.D. (%CV); * p<0.05 ; ** p<.001
GAPDH was selected as the reference gene for Q-PCR analysis of mRNA expression of
organic anion transporters Oat3, P-gp, Oatp1c1, and Oatp1a4. Analysis revealed large
differences between expression levels of transporter mRNA in LBW individuals compared to
controls. In Oat3 mRNA expression, there was a sex-dependent decrease in expression; the
female LBW group at day 90 showed a 14-fold decrease in expression compared to a 2-fold
decrease in the males. However, there was an almost 100-fold decrease in the expression of this
transporter by males at day 150. The magnitude of this decrease was smaller in females
(approximately 17-fold) at day 150 (see figure 4).
Figure 4: Expression of OAT3 mRNA in male and female LBW groups. Represented as fold
changes in mRNA expression relative to control.
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P-gp mRNA analysis revealed a similar trend to the expression of Oat3. At day 90, the
female LBW group shows a more pronounced decrease in P-gp mRNA expression than the male
LBW group, but at day 150, the males show a much more marked decrease in expression

*
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compared to the controls (14-fold decrease in males compared to 2-fold decrease in females) (see
figure 5).
Figure 5: Expression of P-gp mRNA in male and female LBW groups. Represented as fold
changes in mRNA expression relative to control.
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PCR analysis of transporters Oatp1c1 and Oatp1a4 showed similar patterns of expression
in LBW males. Generally, there is a small decrease in transporter expression at day 90, followed
by a much larger-scale decrease in expression at day 150 (see figures 6 and 7). However, this
trend is not observed in the females. Day 90 LBW females express 13-fold less Oatp1c1 than
controls at day 90, but then at day 150, they recover some expression and show only a 10-fold
decrease in expression. The opposite is true for female expression of Oatp1a4. At day 90, there is
a 1-fold decrease in expression relative to the controls, followed by a 4-fold decrease in
expression at day 150.
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Figure 6: Expression of Oatp1c1 mRNA in male and female LBW groups. Represented as fold
changes in mRNA expression relative to control.
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Figure 7: Expression of Oatp1a4 mRNA in male and female LBW groups. Represented as fold
changes in mRNA expression relative to control.
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Discussion
The LPD treatment did not affect the expression of GAPDH in the brain. Selection of a
housekeeping gene with stable expression across treatment groups for normalization of PCR
studies is important in order to discern changes in the gene transcript expression of genes of
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interest32. Because of the stable expression of GAPDH, this gene is an ideal internal control for
gene expression studies in brain tissue of our LPD model.
The functional data provided by analysis of indoxyl sulfate concentrations in brain and
serum show that there is less of this compound accumulating in the brain tissue in LBW subjects
and more is present in the serum, suggesting either less influx transport or greater efflux
transport. As indoxyl sulfate is a substrate for Oat3, an efflux transporter, we might expect to see
an increase in the protein expression of Oat3 in the plasma membranes of BBB endothelial cells.
By western blot analysis, this is exactly the trend that is observed. There is more Oat3
protein in the plasma membrane fraction of brain homogenate from LBW subjects. However,
when the mRNA expression of Oat3 and other OATs is analyzed, a general decrease in mRNA
expression is observed in LBW subjects compared to controls.
There are several reasons why this might occur. It is possible that the LBW phenotype
induces extra stability of mRNA transcripts so that a greater number of proteins can be translated
from each transcript.
Lucas et. al. illuminates possible mechanisms by which maternal protein restriction might
act to induce LBW and organ-specific effects. The first is relatively simple: that nutrient
restriction might fail to fuel growth processes33. This might explain several of the reductions in
cell number in LBW organs. As mentioned above, maternal LPD was shown to decrease kidney
size in offspring and also decrease nephron number by 30% 11. Additionally, maternal LPD has
been shown to reduce blood vessel density in the cerebral cortex14.
But when normalized to organ size, differences in the expression of transporters still
exist. Lucas suggests that nutrients could possibly act directly or indirectly on receptors in
sensitive tissues, and the responses initiated in these cells could lead to adaptive gene expression,
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or perhaps the nutitional environment could lead to adaptive clonal selection which would allow
for proliferation of the cell type best suited to the limited nutrient density33. It may be for these
reasons that programming effects are seen later in life, as far as 150 days after birth in our rodent
model and late into adulthood in humans. In a study conducted on individuals whom were inutero while their mothers suffered the Dutch Hunger Winter, it was found that periconceptional
exposure to conditions of famine influenced the methylation status of the insulin-like growth
factor II (IFG2) gene in offspring34. Epigenetic modifications that persist later in life could be a
mechanism of regulatory gene expression induced by maternal LPD.
The programming effects observed in this study were not uniform between sexes,
however. The maternal LPD rat model has been shown to decrease the serum concentrations of
luteinizing hormone (LH) and testosterone in male offspring 35. Buist, et. al. observed that the
expression of kidney Oat1 and liver Oat3 were decreased in gonadectomized male rats, and
female gonadectomized rats showed decreases in Oat1, Oat3, and kidney Oat235. Given that male
and female rats show different expression patterns of transporters and drug-metabolizing
enzymes to begin with36, it is clear that sex hormone regulation might be a cause for the
differences between the sexes in mRNA and protein expression that observed in the current
study.
Heart disease, diabetes, and hypertension are chronic diseases which require
pharmaceutical intervention. As the LBW phenotype is associated with development of these
conditions, it is highly likely that while these individuals constitute a small portion of the overall
population; they will comprise a large portion of the population requiring medication long-term
for chronic disease. Changes in the transporters that mediate the brain’s ability to maintain
homeostasis could have a very large impact on how LBW individuals process pharmaceutical
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agents. Over-expression of efflux transporters could mean that certain neuroactive drugs do not
reach the correct concentrations in the brain because they are flushed out at a much faster rate
than anticipated. Alternatively, over-expression of influx transporters could cause accumulation
in the brain of endogenous or exogenous compounds to a concentration that is harmful to brain
tissue.
It is important to understand how the LBW phenotype might affect drug transport
proteins in order for clinicians to make informed decisions about drug dosage that will optimize
treatment and minimize harm.
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